Analytic Investors’s Enanta Pharmaceuticals ENTA Stock Holding History

Analytic Investors’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-13,440	Closed	-$683K	–	553
2014 Q4	$683K	Sell	13,440 -29,062	-68%	-$1.3M	0.01%	398
2014 Q3	$1.68M	Sell	42,502 -12,055	-22%	-$481K	0.02%	290
2014 Q2	$2.35M	Buy	54,557 +37,327	+217%	+$1.42M	0.04%	236
2014 Q1	$689K	Sell	17,230 -274	-2%	-$9.95K	0.01%	405
2013 Q4	$478K	Buy	+17,504	New	+$424K	0.01%	386

Other funds holding ENTA

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

ACM

Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

MVM

McClain Value Management New Canaan, Connecticut $50.9M AUM 16.06% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Analytic Investors's ENTA Position: Q1 2015 in Review

Analytic Investors sold out of Enanta Pharmaceuticals (ENTA) in Q1 2015, closing a stake of 13,440 shares — an estimated $683K sold.

Analytic Investors first reported a position in ENTA in Q4 2013 and held it in 5 quarters. The position peaked at $2.35M in Q2 2014. 117 funds tracked by Wall St. Rank hold ENTA as of Q1 2015.

Analytic Investors reported no remaining Enanta Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
Analytic Investors sold 13,440 Enanta Pharmaceuticals shares in Q1 2015, an estimated $683K.
Analytic Investors first reported a position in Enanta Pharmaceuticals in Q4 2013 and held it in 5 quarters.
Analytic Investors's Enanta Pharmaceuticals position peaked at $2.35M in Q2 2014.
117 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2015.

Based on Analytic Investors's 13F filing for Q1 2015, filed 21 May 2015.